Scientists Map Complete Human Epigenome, Opening New Era of Personalised Medicine
March 28, 2026
HEALTH
HEALTH
New Drug Ozempic Successor Tirzepatide Shows 22% Body Weight Redu...
Tirzepatide achieves 22.5% body weight reduction in real-world Phase 4 data, with India approval for obesity treatment secured.
Last updated: October 28, 2025 12:00 am
•
1 Min Read
Share
Tirzepatide achieves 22.5% body weight reduction in real-world Phase 4 data, with India approval for obesity treatment secured.
Results from the Phase 4 real-world evidence study of tirzepatide — sold as Mounjaro by Eli Lilly — demonstrated an average body weight reduction of 22.5% over 72 weeks in obese patients without type 2 diabetes, confirming even stronger effectiveness in clinical practice than in the original trial. The drug, which acts on both GLP-1 and GIP receptors, produced clinically significant improvements in blood pressure, triglycerides, and sleep apnoea severity. Tirzepatide supply constraints that plagued 2024 have been largely resolved following Eli Lilly expanded manufacturing investment, and the drug has received price approvals from insurance regulators in 14 additional countries. India Drug Controller General approved tirzepatide for obesity treatment in adults with a BMI above 30, with reimbursement under consideration for Ayushman Bharat for patients with comorbid diabetes.
Charles C. James is a Senior Political Correspondent with over a decade of experience covering Capitol Hill, federal policy, and national elections across the United States.
You May Also Like
HEALTH
Harvard Study Finds Daily Yoga Reduces Cortisol Levels by 30% in Stressed Adults
March 5, 2026